ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 1343

Are There Differences Between Young and Older Onset Early Rheumatoid Arthritis and Does This Impact Outcomes? An Analysis From The Canadian Early Arthritis Cohort

Michael Arnold1, Vivian P. Bykerk2, Gilles Boire3, Boulos Haraoui4, Carol A. Hitchon5, J. Carter Thorne6, Edward Keystone7 and Janet E. Pope8, 1Medicine/Rheumatology, University College Dublin, Ireland, Dublin, Ireland, 2Divison of Rheumatology, Hospital for Special Surgery, New York, NY, 3Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, 4Rheumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada, 5Rheumatology, University of Manitoba, Winnipeg, MB, Canada, 6Southlake Regional Health Centre, Newmarket, ON, Canada, 7Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, University of Toronto, Toronto, ON, Canada, 8Medicine, Divsion of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: , , ,

Session Information

Title: Rheumatoid Arthritis - Clinical Aspects II: Predictors of Disease Course in Rheumatoid Arthritis - Treatment Approaches

Session Type: Abstract Submissions (ACR)

Background/Purpose: To determine the impact of age on disease and remission in early rheumatoid arthritis (ERA).

Methods: Data from the Canadian Early Arthritis Cohort (CATCH) were examined at baseline, 6 and 12 months. Patients were divided into three groups based on age. ANOVA and regression models were performed to determine the impact of age on DAS28 and remission at 12 months.

Results: 1809 patients were assessed at baseline, 442 (24.4%) ‘young’ (<42 years), 899 (49.7%) ‘middle-aged’ (³ 42, <64 years) and 468 (25.9%) ‘old’ (³64 years); 72.9% were female, 63.8% met 2010 ACR/EULAR Classification Criteria for RA, symptom duration at first visit was 186.0 days, DAS28 4.9, HAQ 1.0; 25.3% had baseline erosions. A significant correlation existed between older age and less percent females, less positive RF and CCP, less meeting RA criteria, shorter symptom duration, more erosions at first visit, higher DAS28 and HAQ at baseline and 12 months, and less DAS28 remission at 12 months (all P<0.003). Age group did not affect the change in DAS28 and HAQ from 0-12 months. Comorbidities increased with age; more DMARDs including methotrexate and steroids and less biologics were used in older age. Age and female had a lesser chance of remission in regression model.

Conclusion:

In ERA, older onset RA patients start and end their first year worse in terms of DAS28 and HAQ, with less meeting RA criteria, less remission, more DMARDs and steroids but less biologic use; however there were no differences between age groups in change in DAS28. 

Disclosure:

M. Arnold,
None;

V. P. Bykerk,

Amgen,

5,

Pfizer Inc,

5,

BMS,

5,

Gennentech,

5,

UCB,

5;

G. Boire,
None;

B. Haraoui,

Amgen, Abbott, Bristol-Myers Squibb, Pfizer, Roche, UCB,

2,

Amgen, Abbott, Bristol-Myers Squibb, Pfizer, Roche, UCB,

8,

Amgen, Abbott, Bristol-Myers Squibb, Pfizer, Roche, UCB,

9;

C. A. Hitchon,
None;

J. C. Thorne,
None;

E. Keystone,

Abbott, AstraZeneca, Biotest, BMS, F. Hoffmann-La Roche, Genentech, Janssen, Lilly, Merck, Nycomed, Pfizer, UCB Pharma ,

2,

Abbott, Amgen, AstraZeneca, BMS Canada, F. Hoffmann-La Roche, Janssen, Pfizer, UCB Pharma,

8;

J. E. Pope,
None.

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/are-there-differences-between-young-and-older-onset-early-rheumatoid-arthritis-and-does-this-impact-outcomes-an-analysis-from-the-canadian-early-arthritis-cohort/